Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT00295503
Phase
PHASE2
Status
Completed

Conditions

  • Mesothelioma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
    15 mg/kg IV every 3 weeks
  • cisplatin — DRUG
    75 mg/m2 IV every 3 weeks
  • pemetrexed — DRUG
    500 mg/m2 every 3 weeks

Study Details

To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab

Key Dates

First listed
Feb 23, 2006
Start date
Feb 28, 2006
Status verified
Sep 2020
Primary completion
Jun 30, 2010
Completion
Aug 31, 2010

Study Design

Enrollment
53 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    cisplatin, pemetrexed, and bevacizumab

Primary Outcome Measure

Progression Free Survival Rate at 6 Months [ Time Frame: patients progression free at 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas Southwestern Medical CenterDallasTexas75390-8852-

Find similar trials in Dallas, TX

By research site
University of Texas Southwestern Medical Center· Dallas, TX

Related Studies